Medicare administration rules could change the price of drugs for Medicare patients

• The Medicare administration rule would change how much drug prices for patients are paid through the 340B program, which would reduce the price of drugs for Medicare patients.
• CMS would modify the reimbursement formula; specifically, it would require paying $800 less per year in average payments for Medicare Part B for the drug. The total would be $1.1 billion in the first year.
• As the rule would be abolished, the CMS would no longer be able to require that the price be reduced; applying Lupron Depot would reduce the reimbursement by 40% from the amount that Medicare would otherwise pay.

The Medicare administration rule would introduce a new rule that could change the price of Medicare-covered drugs for patients. Citing The Associated Press, it is possible that the change would cost more than $1.1 billion in the first year.

The proposal would apply to the 340B program, which would help hospitals. Under the proposal, the 340B program would be required to reduce drug prices by using the same system. Under the proposal, the 340B program would be required to reduce drug prices for Medicare patients.

With the CMS proposal, the reimbursement formula for Medicare Part B drugs would be changed, which would require paying $800 less per year in average payments. The total amount would be $1.1 billion for all patients.

Also in the materials, it is stated that the proposal could save nearly $20 billion over 10 years. The proposal's sponsor, Bill, said that it would not be possible to change the official rules and that, if it were implemented, it would not be possible to reduce the cost of drugs for Medicare patients.

The proposal would apply to Lupron Depot. The materials state that, if the 340B program is used, it could reduce the price to $700 for Medicare, while the reimbursement would be about $4,000, and the additional amount would be $1,000 for the patient. In other words, the proposal would reduce the reimbursement by 40% of the amount that Medicare would pay.

If the rule were abolished, then, in that case, it would be possible to change the price of the drug. The materials also state that in 2018, the U.S. Department of Health and Human Services issued a rule that would allow Medicare patients to pay less for drugs, but in 2022, the U.S. Supreme Court upheld a decision that the rule could not be applied to 340B.

The materials say that, in 2025, the rule could be signed by the end of the year, and the results of the proposal would be that the program would reduce the price of drugs for Medicare patients by 33.4%, while the drug would be sold at a lower price.

Tags: USA/Well-being/Politics